Walleye Capital LLC Purchases 36,329 Shares of IDEAYA Biosciences, Inc. $IDYA

Key Points

• Walleye Capital LLC increased its stake in IDEAYA Biosciences by 170.5%, acquiring 36,329 additional shares, bringing its total ownership to approximately 57,641 shares valued at $944,000.
• Wall Street analysts have a consensus rating of "Moderate Buy" for IDEAYA Biosciences, with price targets ranging from $25.00 to $72.00.
• Despite a reported quarterly loss of ($0.88) EPS, IDEAYA Biosciences generated revenues of $6.00 million, exceeding analysts' expectations.

Walleye Capital LLC boosted its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 170.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,641 shares of the company's stock after purchasing an additional 36,329 shares during the quarter. Walleye Capital LLC owned about 0.07% of IDEAYA Biosciences worth $944,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new stake in shares of IDEAYA Biosciences during the 4th quarter valued at $431,000. Mariner LLC raised its holdings in shares of IDEAYA Biosciences by 9.8% during the 4th quarter. Mariner LLC now owns 9,775 shares of the company's stock worth $251,000 after buying an additional 869 shares in the last quarter. Hsbc Holdings PLC raised its holdings in shares of IDEAYA Biosciences by 66.6% during the 4th quarter. Hsbc Holdings PLC now owns 38,690 shares of the company's stock worth $980,000 after buying an additional 15,465 shares in the last quarter. AXA S.A. raised its holdings in shares of IDEAYA Biosciences by 20.1% during the 4th quarter. AXA S.A. now owns 249,702 shares of the company's stock worth $6,417,000 after buying an additional 41,722 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in shares of IDEAYA Biosciences by 3.6% during the 4th quarter. Ameriprise Financial Inc. now owns 288,002 shares of the company's stock worth $7,401,000 after buying an additional 10,072 shares in the last quarter. 98.29% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on IDYA. Royal Bank Of Canada raised IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and lowered their price target for the stock from $57.00 to $30.00 in a report on Wednesday, July 9th. Wells Fargo & Company began coverage on IDEAYA Biosciences in a report on Thursday, June 26th. They set an "overweight" rating and a $44.00 price target for the company. JPMorgan Chase & Co. boosted their price target on IDEAYA Biosciences from $66.00 to $72.00 and gave the stock an "overweight" rating in a report on Monday, July 28th. The Goldman Sachs Group raised IDEAYA Biosciences to a "hold" rating and set a $25.00 price target for the company in a report on Thursday, July 10th. Finally, TD Cowen assumed coverage on IDEAYA Biosciences in a report on Tuesday, July 22nd. They issued a "buy" rating for the company. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, IDEAYA Biosciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $47.10.

IDEAYA Biosciences Stock Down 1.5%

Shares of IDYA opened at $24.55 on Friday. IDEAYA Biosciences, Inc. has a 12-month low of $13.45 and a 12-month high of $40.25. The business has a 50-day simple moving average of $23.26 and a two-hundred day simple moving average of $20.46. The stock has a market cap of $2.15 billion, a PE ratio of -6.48 and a beta of 0.09.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.03). The business had revenue of $6.00 million during the quarter, compared to analyst estimates of $3.48 million. During the same period in the previous year, the firm posted ($0.68) earnings per share. The firm's quarterly revenue was up NaN% on a year-over-year basis. On average, equities research analysts expect that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

Want to see what other hedge funds are holding IDYA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.